Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10022

Result Summary for APV10022

Result Summary

Protocol ID:	APV10022
Clinical Study ID:	APV10022
Official Title:	A Phase I, Randomized, Open Label, Two-Period, Four-Arm, Balanced Cross-over, Steady-state, Drug Interaction Study between Ritonavir 100mg BID and FPV 700mg BID and between Ritonavir 100mg BID and AGENERASE† 600mg BID in Healthy Adult Subjects
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	M.B. Wire, M.J. Shelton, Y. Lou, K.L. Baker, L. Staley, G. Thomas, M.M. Berrey. Ritonavir (RTV) Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Co-administered with either Fosamprenavir (FPV) or APV (APV10022). 44th ICAAC, 10/30/2004 Washington, DC; USA . A-450